Analysts who follow Immunitybio Inc (IBRX) on average expect it to decline -26.71% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns Immunitybio Inc an Analyst Ranking of 36, which means it ranks higher than 36 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating IBRX a Buy today. Find out what this means to you and get the rest of the rankings on IBRX!